Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | SVP, Chief Business Officer | November 18, 2024 | November 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date November 18, 2024 · Filed November 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 284,685 |
Reported balance
After 2024-11-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-11-18 · Sale · Disposed 5,360 · Balance 284,685 F1: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person. F2: The Reporting Person acquired 2,014 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.
F2: The Reporting Person acquired 2,014 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2024 Filed Nov 20, 2024 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 5,360 | $4.08 | $21,868.80 |
DisclosureSEC source: 0000950170-24-129228 · ownership.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,685 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: The Reporting Person acquired 2,014 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2024. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 22,725 | $6.45 | $146,576.25 |
DisclosureSEC source: 0000950170-24-063482 · ownership.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,031 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units and performance-based restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionPerformance-based Restricted Stock Unit · Derivative | 37,120 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-029910 · ownership.xml · derivative · entry 2 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 37,120 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each PSU represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs are earned upon the Issuer's Class A Common Stock achieving a specified price per share. F2 · derivative.exercise_date: Each PSU represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs are earned upon the Issuer's Class A Common Stock achieving a specified price per share. F3 · balance_after: Additional PSUs may vest upon the Issuer's Class A Common Stock achieving specified prices per share beyond the previously achieved vesting targets. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 37,120 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-029910 · ownership.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted on March 8, 2023. The earned PSUs were certified on February 12, 2024, and March 7, 2024, and vested on March 8, 2024. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 01:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantPerformance-based Restricted Stock Unit · Derivative | 32,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015548 · ownership.xml · derivative · entry 3 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,656 Underlying: Class A Common Stock · 32,656 shares Expires 2027-02-28 F5 · derivative.exercise_price: Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share. F5 · derivative.exercise_date: Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 01:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 65,312 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015548 · ownership.xml · nonDerivative · entry 2 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,636 F4 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 01:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 9,846 | $15.24 | $150,053.04 |
DisclosureSEC source: 0000950170-24-015548 · ownership.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,324 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.85 to $15.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The reporting person acquired 796 shares of Class A Common Stock under the issuer's employee stock purchase plan on December 31, 2023. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,287 | $9.69 | $31,851.03 |
DisclosureSEC source: 0001209191-23-056446 · doc4.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,374 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: The reporting person acquired 1,334 shares of Class A common stock under the issuer's employee stock purchase plan on June 30, 2023. Read SEC document |
| May 22, 2023 Filed May 24, 2023 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 6,305 | $10.12 | $63,806.60 |
DisclosureSEC source: 0001209191-23-031873 · doc4.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,327 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantPerformance-based Restricted Stock Units · Derivative | 37,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017873 · doc4.xml · derivative · entry 2 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,118 Underlying: Class A Common Stock · 37,118 shares Expires 2026-02-28 F2 · derivative.exercise_price: Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share. F2 · derivative.exercise_date: Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 74,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017873 · doc4.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,632 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 23:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,822 | $11.31 | $20,606.82 |
DisclosureSEC source: 0001209191-23-014276 · doc4.xml · nonDerivative · entry 2 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,396 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,751 | $11.41 | $19,978.91 |
DisclosureSEC source: 0001209191-23-014276 · doc4.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,218 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The reporting person acquired 756 shares of Class A Common Stock under the issuer's employee stock purchase plan on December 31, 2022. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,335 | $11.56 | $38,552.60 |
DisclosureSEC source: 0001209191-22-058607 · doc4.xml · nonDerivative · entry 1 Davis Andrew · CIK 0001932525 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,213 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: The reporting person acquired 1,032 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.